COMP <GO>
TVTX vs MRK // PIOTROSKI F-SCORE QUALITY
Travere Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: TVTX 4
— MRK 9
■ METRIC PARITY
LAST: $50.39 (-0.36%) • MKT CAP: $4.77B
piotroski-score
7/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVTX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TVTX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | TVTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.00% | 20.70% | -33.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.33% | 3.42% | -3.09 | MRK | /fcf-yield <GO> |
| Operating Margin | -12.80% | 34.30% | -47.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | -5.20% | 28.10% | -33.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 110.50% | 1.30% | +109.20 | TVTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.44 | 5.19 | -1.75 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.4 | 56.9 | -21.42 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | TVTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 18.4x | -0.40 | TVTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.77B | $361.02B | -$356.25B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TVTX REV | MRK REV | TVTX GROSS % | MRK GROSS % | TVTX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $490.7M | $65.01B | 97.9% | 74.8% | $15.7M | $12.36B |
| FY 2024 | $233.2M | $64.17B | 96.7% | 76.3% | -$248.0M | $18.10B |
| FY 2023 | $145.2M | $60.12B | 44.0% | 44.0% | -$286.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVTX // BETA 1.08
MRK // BETA 0.92